MedTrace Logo

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease

NCT02656017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2022-08-09

Study results available
· View outcomes & findings →

Summary

This study will test to see if metformin is safe and if it is tolerated compared to placebo in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages of chronic kidney disease. We will also measure its effect on progression of kidney disease as reflected in the kidney size and the kidney function, along with its effect on kidney pain and quality of life.

Conditions

  • Polycystic Kidney, Autosomal Dominant

Interventions

DRUG

Metformin

Monitoring of tolerability and symptoms.

OTHER

Placebo

Monitoring of tolerability and symptoms.

Sponsors & Collaborators

  • Tufts Medical Center

    collaborator OTHER

  • University of Maryland, Baltimore

    collaborator OTHER

  • University of Southern California

    collaborator OTHER

  • United States Department of Defense

    collaborator FED

  • Kyongtae Ty Bae, M.D., Ph.D.

    lead OTHER

Principal Investigators

  • Kyongtae Bae, MD, PhD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-27
Primary Completion
2020-12-07
Completion
2020-12-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656017 on ClinicalTrials.gov